Why immunotherapy fails ? Stephen Durham Imperial College and Royal Brompton Hospital, London UK.

Slides:

Advertisements

Similar presentations

Mechanisms of sensitization, disease development and desensitization: towards novel approaches for prevention and therapy Ronald van Ree Academic Medical.

Advertisements

Asthma and Inhalant Allergens

Food Allergy Update Thomas Flaim, M.D.. Prevalence of Food Allergy Prevalence rate is 6% in children < 3 years of age; 4% in adults Prevalence rate is.

Allergen Immunotherapy: From Shots to Tablets Susan Waserman MSc MDCM FRCPC Professor of Medicine Division of Clinical Allergy and Immunology Life and.

Immunotherapy: Evidence in atopy Carla Irani, M.D Allergy/Clinical Immunology.

Management of Allergic Rhinitis

Immunopathological reaction (reaction of hypersensitivity) type I.

Dr Narayana pradeep Consultant Pulmonologist Carewell hospital KasaragodKERALA.

Dermot Ryan, FRCGP, Woodbrook Medical Centre, Loughborough, United Kingdom Allergy and Respiratory Research Group, Centre for Population Health Sciences:

Are rhinitis and asthma two manifestations of one disease? Stephen R. Durham Allergy and Clinical Immunology Royal Brompton Hospital and Imperial College.

Agency for Healthcare Research and Quality (AHRQ)

Allergen regulation in the future : what will be the place for recombinant allergens ? Jacqueline DAYAN-KENIGSBERG European Academy of Allergology and.

Use of Multiple Allergen Mixes in Immunotherapy Harold S. Nelson, MD Professor of Medicine National Jewish Health University of Colorado Denver School.

Diagnostic approach to the allergic patient. Allergic conditions in Israel.

1 Environmental Exposure Units for Phase 3 Studies Ronald L. Rabin, MD Chief, Laboratory of Immunobiochemistry Center for Biologics Evaluation and Research.

T-cell Immunoregulation and the Response to Immunotherapy Harold S. Nelson. MD Professor of Medicine National Jewish Health and University of Colorado.

SLIT: dealing with trouble, doing it right. Giovanni B Pajno MD Professor of Pediatrics Department of Pediatrics – Allergy Unit University of Messina Italy.

Downloaded from – Use of Montelukast for the Treatment of Seasonal (Spring) Allergic Rhinitis.

Which Patients for Subcutaneous Immunotherapy? Harold S. Nelson. MD Professor of Medicine National Jewish Heath University of Colorado Denver School of.

Monotherapy for the polysensitized patient Noel Rodriguez-Perez, MD Professor of pediatrics State University of Tamaulipas, Mexico.

내과 R2 이지영. INTRODUCTION  Asthma  Allergic airway inflammation,Th2-weighted process  Biomarkers  Phenotypic distinctions  Development of personalized.

Sublingual immunotherapy in allergic conjuctivitis with house dust and dust mite allergies DR VIPUL SHAH.

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy Ravi S. Swamy, MD, Neha Reshamwala,

Immunotherapy for Allergic Rhinitis

Sublingual Immunotherapy

Fadhel Saleh 1, Rabab A. Hussain 2, Fadheela A. Saleh 2

ALLERGEN SPECIFIC IMMUNOTHERAPY: EFFICACY & NEW DEVELOPMENTS

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms Anna Slovick, MRCS, Abdel Douiri, PhD,

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Volume 11, Pages (September 2016)

HATSJOE Study Symptomatic treatment of pollen-related allergic rhinoconjunctivitis in children: a randomized controlled trial.

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Immunotherapy for Food Allergy: Are We There Yet?

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Oral immunotherapy and omalizumab for food allergy

Innate microbial sensors and their relevance to allergy

Clinical Developments in Allergen Immunotherapy

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32 Verena Niederberger, MD, Angela Neubauer, PhD,

Advances in Peanut Allergen Immunotherapy

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms Natasha C. Gunawardana,

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of.

Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies Louisa K. James, PhD, Mohamed H. Shamji,

T lymphocytes in asthma: Bronchial versus peripheral responses

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms Anna Slovick, MRCS, Abdel Douiri, PhD,

Mohamed H. Shamji, PhD, Janice A. Layhadi, MSc, Guy W

House Dust Mite Respiratory Allergy: An Overview of Current Therapeutic Strategies Moisés A. Calderón, MD, PhD, Jörg Kleine-Tebbe, MD, Allan Linneberg,

Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti–IL-4: A randomized controlled trial Adam M. Chaker, MD, Mohamed H. Shamji,

Legends in allergy: Philip S. Norman and Lawrence M

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation Abel Suárez-Fueyo, PhD, Tania.

Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis Stephen R. Durham,

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic.

Mohamed H. Shamji, PhD, FAAAI, Stephen R. Durham, MD, FRCP

House dust mite sublingual immunotherapy: Results of a US trial

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years Ronald Dahl, MD,

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD

Fig. 2. Putative mechanisms of oral tolerance induction in the gut

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

The future of biologics: Applications for food allergy

Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response Meri K Tulic, PhD, Pierre-Olivier Fiset,

Presentation transcript:

Why immunotherapy fails ? Stephen Durham Imperial College and Royal Brompton Hospital, London UK

Declaration Research funding, consultancy and lecture fees from ALK Abello Lecture fees from Allergy Therapeutics

wrong set up wrong patient wrong allergen(s) wrong dose wrong duration Why immunotherapy fails ?

right set up right patient right allergen(s) right dose right duration Why immunotherapy succeeds ?

right set up right patient right allergen(s) right dose right duration Why immunotherapy succeeds ?

Immunotherapy clinic

Leadership/organisation of allergy clinic Staff competencies (induction/training) Clinic facilities –bookings, observation space –storage for vaccines / skin test reagents –safety procedures –rescue equipment Immunotherapy protocols Alvarez-Cuesta E et al Allergy 2006; 61 Suppl. 82: 1-20

Staff competencies Evaluation of the patients’ condition Entering data in “Immunotherapy Record Form” Injection technique Dose modification Active observation of patients Early recognition of anaphylactic reactions Treatment /monitoring of anaphylactic reactions How to perform scheduled assessments Factors determining whether to continue/stop IT Alvarez-Cuesta E et al Allergy 2006; 61 Suppl. 82: 1-20

right set up right patient right allergen(s) right dose right duration Why immunotherapy succeeds ?

Selection of patients for immunotherapy Symptoms induced by allergen IgE to relevant allergen (SPT/RAST) Symptoms due to one or few allergens No contra-indications (severe asthma, beta/blockers, inability to comply with IT)

Arvidsson M, Löwhagen O Rak S J Allergy Clin Immunol 2002;109: Immunotherapy in adults with birch allergy

Franklin Adkinson N et al New Engl J Med 1999; Immunotherapy in children with perennial asthma and multiple allergen sensitivities

right set up right patient right allergen(s) right dose right duration Why immunotherapy succeeds ?

Selection of allergen extracts Standardisation - in-house reference standards (IHRs) - units of biologic potency - major allergen content (5-20 mcg major Ag) - recombinant allergens Documented benefit (controlled trials) - efficacy - safety - children and adults - longterm effects

J Allergy Clin Immunol 2006; 117: centres, n= ,000 SQ, 10,000 SQ and placebo

Grass pollen immunotherapy: UK immunotherapy study Frew AJ et al, J Allergy Clin Immunol 2006; 117:

p<0.001 p=0.027 Rhinoconjunctivitis QoL score BaselineSeasonBaseline/Season 100,000 SQ-U10,000 SQ-UPlacebo P=0.027 Frew AJ et al, J Allergy Clin Immunol 2006; 117:

right set up right patient right allergen(s) right dose right duration Why immunotherapy succeeds ?

J Allergy Clin Immunol 2007; 120:

Sublingual Grass Tablet Immunotherapy J Allergy Clin Immunol 2007; 120:

Sublingual Grass Tablet Immunotherapy

Randomised DBPC trial (n=855). 3 doses v placebo 2,500 SQ-T 25,000 SQ-T 75,000 SQ-T Once daily 8 weeks pre-season and continued throughout season

Durham SR et al. J Allergy Clin Immunol 2006; 117: Sublingual Grass Tablet Immunotherapy

right set up right patient right allergen(s) right dose right duration Why immunotherapy succeeds ?

right set up right patient right allergen(s) right dose right duration - efficacy - tolerance Why immunotherapy succeeds ?

17% reduction in average seasonal daily rhinoconjunctivitis symptom (p<0.05) 23% reduction in average seasonal daily medication scores ( p<0.05) 8 Weeks Pre-Seasonal Treatment Calderon MA et al. Allergy 2007

> 8 Weeks Pre-Seasonal Treatment 37% reduction in average seasonal daily rhinoconjunctivitis symptom (p<0.0001) 47% reduction in average seasonal daily medication scores ( p<0.0001) Calderon MA et al. Allergy 2007

right set up right patient right allergen(s) right dose right duration - efficacy - tolerance (persistent efficacy after withdrawal) Why immunotherapy succeeds ?

Durham SR et al New Engl J Med 1999;341: Grass pollen IT in adults: 3 years duration induces tolerance

House dust mite IT in children : 3 years duration induces tolerance Des Roches A et al, Allergy 1996; 51 :430-3

J Allergy Clin Immunol 2008;12: Can sublingual immunotherapy induce tolerance?

right set up right patient right allergen(s) right dose right duration - efficacy - tolerance Why immunotherapy succeeds ?

wrong set up wrong patient wrong allergen(s) wrong dose wrong duration - no efficacy - no tolerance Why immunotherapy fails?

Immunotherapy (high dose Ag) Th1 IFN  IgG T r IL-10 TGF-  IgG4 IgA APC Natural exposure (low dose Ag) + IgE Th2 B cell Eosinophil IgE IL-4 IL-5 Allergy (-) Robinson DS, Larche ML and Durham SR J Clin Invest 2004; 114:

Two types of regulatory T cells Tr1 Th3 Tr1 cells IL-10 Foxp3? Th3 cells TGF-  Adaptive Thn T reg CD4 + CD25 + T cells Foxp3 transcription factor Natural Thymus

J Allergy Clin Immunol 2008; April 17 th epub Phenotypic Tregs in the nasal mucosa CD3 CD25 Foxp3 CD3 IL-10 Foxp3 Controls hayfever Immunotherapy

Th2 responses prevent tolerance induction? Positive feedback Amplifier naivenaive TregTreg FOXP3 TGF-β, IL-10 IL-27IL-35 IL-27IL-35 NFAT Th2Th2 GATA3 resistor negative feedback Anti-IL-4 directed therapy to augment tolerance induction against allergens IL-4 TGF-  IL-10 Mantel P-Y et al, PLOS Biology 2007; 5 (12): e329

Can we predict success or failure of immunotherapy?

late phase response IL-10 production Duration of allergen immunotherapy (weeks) Change in response 2 weeks Grass pollen count Time course of biomarkers during immunotherapy J Allergy Clin Immunol 2008; 121(5):

Early skin response late phase response IgE-FAB inhibition Duration of allergen immunotherapy (weeks) Change in response IgG4 Duration of allergen immunotherapy (weeks) Change in response 4 weeks 8 weeks Late allergen-induced Skin Response Grass Pollen season Time course of changes in IL-10 and IgG-associated inhibitory activity J Allergy Clin Immunol 2008; 121(5): Pollen count Time course of biomarkers during immunotherapy

MAY JUNE JULY AUGUST

r= p= 0.9 Symptom/Medication score Phl p 5 specific IgG4 (% binding) 100 p = r= % Inhibition of allergen/IgE binding to B cells Symptom/Medication score Correlation between clinical response (Sx/Rx) IgG4 and IgE-FAB inhibitory activity IgG4IgE-FAB Shamji M et al 2008, unpublished

Immunotherapy (high dose Ag) Th1 IFN  IgG T r IL-10 TGF-  IgG4 IgA APC Natural exposure (low dose Ag) + IgE Th2 B cell Eosinophil IgE IL-4 IL-5 Allergy (-) Robinson DS, Larche ML and Durham SR J Clin Invest 2004; 114:

Allergy and Clinical Immunology, Imperial College and Royal Brompton Hospital, London, UK M Calderon K T Nouri-Aria G Paraskavopoulos D R WilsonM R JacobsonL Wilcock C Pilette J N Francis C Schmidt-Weber S RadulovicM Shamji S J Till